Dec 4, 2020 · Venetoclax is the first selective BCL2 inhibitor, and the first of a new class of anticancer drug (BH3-mimetics) to be approved for routine clinical practice, currently in chronic …

Herein, we mainly discuss the BCL-2-specific BH3 mimetic venetoclax, the first United States Food and Drug Administration (FDA)-approved BCL-2 inhibitor, which has achieved …

Oct 28, 2017 · We outline the development and uses of these unique anti-apoptotic inhibitors and how to possibly combine them with other anti-cancer agents using dynamic BH3 profiling …

We outline the development and uses of these unique anti-apoptotic inhibitors and how to possibly combine them with other anti-cancer agents using dynamic BH3 profiling (DBP) to …

Mar 5, 2024 · As their name suggests, BCL2 inhibitors work by targeting a family of proteins known as BCL2, which are especially abundant in certain types of cancer cells. Members of …

Oct 12, 2023 · BCL-2 inhibitors have evolved into an important means of treating cancers by inducing tumor cell apoptosis. As the most extensively investigated BCL-2 inhibitor, venetoclax …

The development of orally bioavailable Bcl-2 family inhibitors, such as AT-101, ApoG2, TW-37 and ABT-263, with the ability to inhibit specifically BH3-Bcl-2 protein–protein interactions at …

BCL-2 Family inhibitors and their targets. Venetoclax (ABT-199) is a BCL2 selective inhibitor and approved for use in CLL, SLL, and AML under the trade name VENCLEXTA ®. ABT-737 …

Dec 4, 2020 · Venetoclax is the first selective BCL2 inhibitor, and the first of a new class of anticancer drug (BH3-mimetics) to be approved for routine clinical practice, currently in chronic …

Here, we provide an overview of the mechanism of action of BCL-2 inhibition, the role of this approach in the current treatment paradigm of CLL, and an in-depth focus on the clinical trials …